Needham Reiterates Hold on Lexicon Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Hold rating on Lexicon Pharmaceuticals (NASDAQ:LXRX).
October 30, 2024 | 9:57 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Joseph Stringer has reiterated a Hold rating on Lexicon Pharmaceuticals, indicating a neutral stance on the stock.
The reiteration of a Hold rating by Needham suggests that the analyst does not see significant short-term catalysts for the stock to move up or down. This neutral stance implies that investors may not expect major changes in the stock price in the immediate future.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100